Clinical Trial Update: Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 pharmacokinetic study assessing Lipo-PGE1 for prevention of veno-occlusive disease after hematopoietic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Veno-occlusive Disease

Drugs mentioned

• Lipo-PGE1 (prostaglandin E1 (liposomal formulation))

Snippet

Sponsor: Seoul National University Hospital | Conditions: Veno-occlusive Disease, Child | Phase 2, Phase 3 | Status: UNKNOWN